Improving treatment for empyema in older patients
Official title: Enhanced Delivery of Thrombolytic Carriers for Empyema
Funded at University of Texas Hlth Ctr at Tyler · NIH-10881730 · Data updated 2026-11-12
This study is looking for better and safer ways to treat empyema in older adults by using new therapies that can help dissolve the fluid without needing surgery, making it easier for those who might have other health problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Ctr at Tyler NIH-funded |
| Lab location | 1 site (Tyler, United States) |
| Project start | July 15, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $609,709 |
| NIH project number | 5R01HL152059-04 |
| Project ID | NIH-10881730 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients aged 65 and older who are diagnosed with empyema and may not be suitable for surgical intervention.
✕Less likely to help
Patients with empyema who are younger than 65 or those who are not experiencing significant health issues may not benefit from this specific research.
What this research studies
This research focuses on enhancing the delivery of thrombolytic therapies for empyema, a condition that can be particularly severe in patients over 65 years old. The study aims to develop more effective and safer forms of intrapleural fibrinolytic therapy (IPFT) that can be used instead of invasive surgical options, which may not be suitable for many elderly patients with other health issues. By using advanced techniques such as ultrasound and specialized liposomal carriers, the research seeks to improve treatment outcomes and reduce complications like bleeding. The approach involves testing new therapies in a validated animal model to ensure their effectiveness before considering human trials.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for empyema, significantly improving recovery rates and quality of life for older patients.
How similar studies have gone: Previous research has shown promise in using advanced delivery systems for thrombolytic therapies, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
-
University of Texas Hlth Ctr at Tyler
Tyler, United States Active
Researchers
- Principal investigator: Komissarov, Andrey — University of Texas Hlth Ctr at Tyler
- Study coordinator: Komissarov, Andrey
Related research
Other NIH-funded projects on the same topics.
-
Lipid damage and a form of cell death that turns on blood clotting
This grant explores how certain lipid byproducts and inflammatory cell death trigger tissue factor to start dangerous blood clots, with the aim of finding targets to prevent clot-related heart and vessel problems.
-
Targeting Runx3 to treat a serious immune disease in children
A new approach aims to help kids with a dangerous immune condition by targeting Runx3 to calm overactive immune cells.
-
Southwest Center for Agricultural Health, Injury Prevention, and Education
A regional center partner network is working to improve safety and health for agricultural workers and their communities through research, outreach, and translation of best practices.
-
Understanding how coronavirus spike proteins change shape to enter cells
A study to better understand how spike proteins on enveloped viruses change shape over time to help viruses enter cells and how antibodies recognize them.
-
Targeting inflammation and clot breakdown to boost empyema treatment
A patient-focused study tests a low-dose alteplase plus an inflammation-blocking peptide to improve drainage and survival for adults with empyema who can’t undergo surgery.
-
Gab2-MALT1 signaling and venous clots: a new path to safer therapies
A doctor-scientist team is studying how a specific cell signaling pathway (Gab2-MALT1) contributes to venous clots, with the aim of finding safer ways to prevent and treat them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.